JATT II Acquisition Corp (NASDAQ:JATT) closed its initial public offering on April 20, 2026, selling 6,000,000 ordinary shares at $10.00 per share for $60,000,000 in gross proceeds before underwriting discounts and expenses.
The ordinary shares began trading on the Nasdaq Global Market under JATT on April 17, 2026, and the company granted underwriters a 45-day option to purchase up to 900,000 additional shares to cover over-allotments. The registration statement was declared effective by the SEC on April 16, 2026.
This announcement highlights the completion of JATT’s IPO, with 6,000,000 shares sold at $10.00 for ...
Analysis
This announcement highlights the completion of JATT’s IPO, with 6,000,000 shares sold at $10.00 for gross proceeds of $60,000,000, and an additional 900,000-share over-allotment option. The stock traded on Nasdaq starting April 17, 2026, near its $10.00 200-day MA and below the $12.3799 52-week high. Investors may watch how post-IPO trading volume, use of proceeds, and any future corporate actions shape the company’s trajectory.
Key Figures
IPO shares:6,000,000 sharesIPO price:$10.00 per shareGross proceeds:$60,000,000+5 more
8 metrics
IPO shares6,000,000 sharesInitial public offering size
IPO price$10.00 per shareInitial public offering price
Gross proceeds$60,000,000Total gross proceeds before fees
Over-allotment option900,000 sharesAdditional shares available to underwriters
Over-allotment window45 daysDuration of underwriters’ option
Trading start dateApril 17, 2026Ordinary shares began trading on NASDAQ
SEC effectiveness dateApril 16, 2026Registration statement declared effective by SEC
IPO closing dateApril 20, 2026Initial public offering closing
Key Terms
initial public offering, underwriting discounts and commissions, over-allotments, registration statement, +3 more
7 terms
initial public offeringfinancial
"announced the closing of its initial public offering of 6,000,000 ordinary shares"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
underwriting discounts and commissionsfinancial
"before deducting underwriting discounts and commissions and other offering expenses"
Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.
over-allotmentsfinancial
"option to purchase up to 900,000 additional ordinary shares at the initial public offering price to cover over-allotments"
An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.
registration statementregulatory
"A registration statement relating to the securities sold in the initial public offering was declared effective"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
prospectusregulatory
"The public offering is being made only by means of a prospectus"
A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.
securities and exchange commissionregulatory
"declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 16, 2026"
A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.
nasdaq global marketfinancial
"ordinary shares began trading on the Nasdaq Global Market (“NASDAQ”) under the ticker symbol “JATT”"
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share on April 20, 2026. Total gross proceeds from the offering were $60,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
The ordinary shares began trading on the Nasdaq Global Market (“NASDAQ”) under the ticker symbol “JATT” on April 17, 2026.
Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 900,000 additional ordinary shares at the initial public offering price to cover over-allotments, if any.
A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 16, 2026. The public offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
JATT II Acquisition Corp is a newly incorporated blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. While the Company may pursue an initial business combination in any business or industry, the Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, the Company intends to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of the management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. The Company expects to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. The Company is sponsored by JATT Ventures II L.P. and is led by Dr. Someit Sidhu, Chief Executive Officer and Chairman of the Board, and Nicholas Fernandez, Chief Financial Officer. The Company’s Board of Directors also includes Verender S. Badial, Arjun Goyal, Jonathon Kluft and Christopher Staral, bringing extensive experience across biotechnology investing, company architecture, and public and private capital markets. Learn more at www.jattacquisition.com.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering (“IPO”) including the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of JATT II Acquisition Corp, including those set forth in the Risk Factors section of JATT II Acquisition Corp’s registration statement and prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. JATT II Acquisition Corp undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contacts:
Nicholas Fernandez Chief Financial Officer 153 Central Avenue C/O 56 Westfield, NJ 07091 201-688-0364
FAQ
How much did JATT (NASDAQ:JATT) raise in its April 20, 2026 IPO?
JATT raised $60,000,000 in gross proceeds from its initial public offering on April 20, 2026. According to the company, the offering comprised 6,000,000 ordinary shares sold at $10.00 per share before underwriting discounts and expenses.
When did JATT (NASDAQ:JATT) begin trading on Nasdaq and under what ticker?
JATT began trading on the Nasdaq Global Market on April 17, 2026 under the ticker JATT. According to the company, trading commenced three days before the offering close and follows the SEC declaring the registration effective on April 16, 2026.
What is the size and price of the shares sold in JATT's IPO (JATT)?
The IPO sold 6,000,000 ordinary shares at an offering price of $10.00 per share. According to the company, this structure produced $60,000,000 in gross proceeds prior to underwriting discounts and expenses.
Does JATT (NASDAQ:JATT) have an over-allotment option and how large is it?
Yes. The company granted underwriters a 45-day option to purchase up to 900,000 additional shares to cover over-allotments. According to the company, this represents a 15% over-allotment option relative to the base shares sold.
Who managed JATT's IPO and where can the prospectus be obtained?
Guggenheim Securities acted as sole book-running manager for the offering. According to the company, prospectus copies are available from Guggenheim Securities' Equity Syndicate Department by mail, telephone, or email as provided by the manager.